Generic Industry, FDA Discuss Use Of PK Studies For Pediatric Exclusivity
Executive Summary
FDA is considering the extent to which pharmacokinetic studies can be used to win six months of market exclusivity under the pediatric provisions of the FDA Modernization Act.